- ISIN
- US4131971040
- CUSIP
- 413197104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 19, 2020
Highlights
- Market Cap
- $1.89B
- Enterprise Value
- $1.34B
- EPS (TTM)
- $2.48
- PE Ratio
- 12.93
- PEG Ratio
- 0.13
- Total Revenue (TTM)
- $899.11M
- Gross Profit (TTM)
- $688.25M
- EBITDA (TTM)
- $221.74M
- Year Range
- $25.52 - $40.87
- Target Price
- $46.80
- ROA (TTM)
- 11.45%
- ROE (TTM)
- 16.00%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
HRMY Performance Chart
Harmony Biosciences Holdings, Inc. (HRMY) is down 14.2% since the beginning of the year. At $32 per share, HRMY is trading 21.5% below its 52-week high of $41. Investors who bought $1,000 worth of HRMY shares 5 years ago would now be looking at an investment worth $967.
Loading charts...
Returns By Period
Harmony Biosciences Holdings, Inc. (HRMY) has returned -14.22% so far this year and -9.09% over the past 12 months.
Harmony Biosciences Holdings, Inc.
- 1D
- 3.85%
- 1M
- -1.50%
- YTD
- -14.22%
- 6M
- -13.24%
- 1Y
- -9.09%
- 3Y*
- -3.02%
- 5Y*
- -0.67%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
HRMY Monthly Returns History
Based on dividend-adjusted daily data since Aug 19, 2020, HRMY's average daily return is +0.05%, while the average monthly return is +0.60%. At this rate, an investment would double in approximately 9.7 years.
Historically, 52% of months were positive and 48% were negative. The best month was Aug 2021 with a return of +29.6%, while the worst month was Oct 2023 at -28.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, HRMY closed higher 48% of trading days. The best single day was Oct 31, 2023 with a return of +19.4%, while the worst single day was Oct 13, 2023 at -30.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.41% | -21.85% | -1.86% | 11.60% | 1.06% | 1.61% | -14.22% | ||||||
| 2025 | 12.67% | -12.69% | -1.95% | -11.21% | 17.07% | -8.41% | 11.33% | 4.86% | -25.29% | 3.66% | 23.52% | 6.04% | 8.75% |
| 2024 | -2.35% | 1.78% | 4.61% | -7.95% | -4.89% | 2.62% | 12.23% | 6.26% | 11.17% | -19.67% | 7.91% | -0.75% | 6.53% |
| 2023 | -12.58% | -8.59% | -25.85% | -1.26% | 7.26% | 1.76% | 0.51% | 2.49% | -9.60% | -28.17% | 23.45% | 11.15% | -41.38% |
| 2022 | -15.90% | 11.43% | 21.75% | -7.42% | -3.20% | 11.86% | 4.02% | -13.44% | 0.87% | 17.41% | 14.94% | -7.81% | 29.22% |
| 2021 | -0.80% | -1.09% | -6.85% | -11.32% | 9.08% | -11.67% | -7.33% | 29.55% | 13.10% | 8.19% | -17.80% | 25.08% | 17.95% |
Benchmark Metrics
Harmony Biosciences Holdings, Inc. has an annualized alpha of -1.26%, beta of 0.84, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since August 20, 2020.
- This stock participated in 141.74% of S&P 500 Index downside but only 73.71% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -1.26%
- Beta
- 0.84
- R²
- 0.07
- Upside Capture
- 73.71%
- Downside Capture
- 141.74%
Return for Risk
Risk / Return Rank
HRMY ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Harmony Biosciences Holdings, Inc. (HRMY) and compare them to S&P 500 Index.
| HRMY | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.22 | 2.24 | -2.46 |
Sortino ratioReturn per unit of downside risk | -0.02 | 3.07 | -3.10 |
Omega ratioGain probability vs. loss probability | 1.00 | 1.41 | -0.41 |
Calmar ratioReturn relative to maximum drawdown | -0.26 | 2.93 | -3.19 |
Martin ratioReturn relative to average drawdown | -0.49 | 13.52 | -14.01 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Harmony Biosciences Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Harmony Biosciences Holdings, Inc. was 68.48%, occurring on Oct 27, 2023. The portfolio has not yet recovered.
The current Harmony Biosciences Holdings, Inc. drawdown is 47.30%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -68.48%Oct 2023 | 10mo 25d | — | 3y 6moDec 2022 - now |
2021 bear market2021 | -49.98%Jul 2021 | 8mo 18d | 8mo 21d | 1y 5moNov 2020 - Apr 2022 |
Bear market2022 | -35.69%May 2022 | 19d | 1mo 27d | 2mo 16dApr 2022 - Jul 2022 |
2020 bear market2020 | -30.25%Sep 2020 | 10d | 1mo 15d | 1mo 25dSep 2020 - Nov 2020 |
Bear market2022 | -24.15%Sep 2022 | 2mo 20d | 1mo 6d | 3mo 26dJul 2022 - Nov 2022 |
Drawdown Indicators
| HRMY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.48% | -56.78% | -11.70% |
Max Drawdown (1Y)Largest decline over 1 year | -34.49% | -9.10% | -25.39% |
Max Drawdown (3Y)Largest decline over 3 years | -50.81% | -18.90% | -31.91% |
Max Drawdown (5Y)Largest decline over 5 years | -68.48% | -25.43% | -43.05% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -47.30% | -0.74% | -46.56% |
Average DrawdownAverage peak-to-trough decline | -35.20% | -10.72% | -24.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.69% | 1.97% | +16.72% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Harmony Biosciences Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Harmony Biosciences Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for HRMY, comparing it with other companies in the Biotechnology industry. Currently, HRMY has a P/E ratio of 12.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for HRMY compared to other companies in the Biotechnology industry. HRMY currently has a PEG ratio of 0.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HRMY relative to other companies in the Biotechnology industry. Currently, HRMY has a P/S ratio of 2.1. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HRMY in comparison with other companies in the Biotechnology industry. Currently, HRMY has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with HRMY
Add Harmony Biosciences Holdings, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with HRMY